title: Dramatic response to Cisplatin window therapy in a boy with advanced metastatic ewing sarcoma.
abstract: Ewing sarcoma (ES) is the second most common type of primary bone malignancy, and retains a high propensity to metastasize; the prognosis of patients with disseminated disease is very poor, with an event-free survival rate of <20%. Current multimodality treatment for ES consists of combined chemotherapy before and concurrent with surgery and local radiotherapy for the involved bone. Cisplatin is one of the most widely used drugs for the treatment of bone tumors in children, but is not currently used in ES. We describe a child with multifocal ES, treated with a phase II trial including a single-drug window therapy, which displayed a dramatic response to 2 courses of cisplatin and had a favorable outcome.
authors.affiliation: Department of Pediatric Hematology and Oncology, ARNAS Civico, Di Cristina and Benfratelli Hospital, Palermo, Italy.
authors.forename: Antonino
authors.initials: A
authors.lastname: Trizzino
authors.forename: Ottavio
authors.initials: O
authors.lastname: Ziino
authors.forename: Antonina
authors.initials: A
authors.lastname: Parafioriti
authors.forename: Marta
authors.initials: M
authors.lastname: Podda
authors.forename: Serena
authors.initials: S
authors.lastname: Tropia
authors.forename: Roberto
authors.initials: R
authors.lastname: Luksch
authors.forename: Paolo
authors.initials: P
authors.lastname: D'Angelo
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000532:radiotherapy
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
references.citation: Cancer Treat Rep. 1981 Sep-Oct;65(9-10):815-22
references.pmid: 6944156
references.citation: Med Pediatr Oncol. 1978;4(2):127-32
references.pmid: 275532
references.citation: Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1021-6
references.pmid: 7197583
references.citation: Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1913-6
references.pmid: 3592719
references.citation: Haematologica. 2001 Jul;86(7):753-60
references.pmid: 11454532
references.citation: Cancer. 2006 Apr 15;106(8):1838-45
references.pmid: 16532434
references.citation: Bone Marrow Transplant. 1995 May;15(5):697-705
references.pmid: 7670398
references.citation: Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):125-35
references.pmid: 9747829
references.citation: Cancer Treat Rep. 1977 Aug;61(5):835-9
references.pmid: 890692
references.citation: Ann Oncol. 1998 Mar;9(3):275-81
references.pmid: 9602261
references.citation: Cancer. 1988 Jan 1;61(1):23-32
references.pmid: 3334950
references.citation: J Clin Oncol. 2000 Sep;18(17):3108-14
references.pmid: 10963639
references.citation: Pediatr Blood Cancer. 2008 Sep;51(3):334-8
references.pmid: 18506764
references.citation: Eur J Cancer. 2007 Mar;43(5):885-90
references.pmid: 17254770
references.citation: Br J Cancer. 2001 Nov 30;85(11):1646-54
references.pmid: 11742482
references.citation: Cancer. 2010 Jan 15;116(2):443-50
references.pmid: 19924786